Skip to main content

Table 3 Epidemiologic profile and clinical characteristics

From: Multi-detector computed tomography and 3Tesla magnetic resonance imaging in assessment of COVID-19 intracranial complications

Demographic and clinical parameters All patients (n = 74) Died patients (n = 43) Alive patients (n = 31) p-value
Sex (male/female) 48/26 27/16 21/10 0.66
Age (years), mean/range 61/23–88 64/23–88 48/45–78 0.001*
Time from onset of symptoms* to brain imaging (days) mean/range 2/1–4 2/1–4 2/1–4 0.58
Clinical characteristics     
 History of smoking 34 23 (67.6%) 11 (32.3%) 0.125
 Obesity 12 10 (83.3%) 2 (16.7%) 0.053
 ARDS 60 29 (48.3%) 31 (51.7%) 0.0004*
 Medical history 59 40 (93.02%) 19 (61.3%) 0.0008*
Previous neurological illness 17 8 (47.1%) 9 (52.9%) 0.292
Follow-up by CT after 2 days 9 4 (44.4%) 5 (55.6%) 0.375
Clinical manifestation     
 Impaired consciousness 22 11 (50%) 11 (50%) 0.357
Neurological findings     
 Infarction 40 23 (57.5%) 17 (42.5%) 0.908
 Hemorrhage and hematomas 19 12 (63.2%) 7 (36.8%) 0.604
  PRES 3 0 (0.0) 3 (100%) 0.037*
  Cerebral edema 2 1 (50%) 1 (50%) 0.813
 WM leucoencephalopathy-related COVID-19 3 2 (66.7%) 1 (33.3%) 0.759
  Microhemorrhage 3 3 (100%) 0 (0.0) 0.259
 Vascular thrombosis 2 0 (0.0) 2 (100%) 0.172
 Acute necrotizing encephalitis 2 2 (100%) 0 (0.0) 0.506
Admission period     
 11–20 days 24 16 (66.7%) 8 (33.3%) 0.301
  1. Used tests: Mann–Whitney U test, Chi-square and Fisher exact test *statistically significant (if p < 0.05)